JBC Origene Your Gene Company

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pak, Y.
Right arrow Articles by George, S. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pak, Y.
Right arrow Articles by George, S. R.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J Biol Chem, Vol. 274, Issue 39, 27610-27616, September 24, 1999


Agonist-induced, G Protein-dependent and -independent Down-regulation of the µ Opioid Receptor
THE RECEPTOR IS A DIRECT SUBSTRATE FOR PROTEIN-TYROSINE KINASE*

Youngshil PakDagger , Brian F. O'DowdDagger §, Jia Bei Wang, and Susan R. GeorgeDagger §parallel **

From the Departments of Dagger  Pharmacology and parallel  Medicine, University of Toronto, Ontario M5S 1A8, Canada, the § Centre for Addiction and Mental Health, Toronto, Ontario M5S 1A8, Canada and the  Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, Maryland 21201

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The µ opioid receptor (MOR) has been shown to desensitize after 1 h of exposure to the opioid peptide, [D-Ala2, N-MePhe4, Gly-ol5]enkephalin (DAMGO), largely by the loss of receptors from the cell surface and receptor down-regulation. We have previously shown that the Thr394 in the carboxyl tail is essential for agonist-induced early desensitization, presumably by serving as a primary phosphorylation site for G protein-coupled receptor kinase. Using a T394A mutant receptor, we determined that Thr394 was also responsible for µ opioid receptor down-regulation. The T394A mutant receptor displayed 50% reduction of receptor down-regulation (14.8%) compared with wild type receptor (34%) upon 1 h of exposure to DAMGO. Agonist-induced T394A receptor down-regulation was unaffected by pertussis toxin treatment, indicating involvement of a mechanism independent of G protein function. Interestingly, pertussis toxin-insensitive T394A receptor down-regulation was completely inhibited by a tyrosine kinase inhibitor, genistein. Tyrosine kinase inhibition blocked wild type MOR down-regulation by 50%, and the genistein-resistant wild type MOR down-regulation was completely pertussis toxin-sensitive. Following DAMGO stimulation, MOR was shown to be phosphorylated at tyrosine residue(s), indicating that the receptor was a direct substrate for tyrosine kinase action. Mutagenesis of the four intracellular tyrosine residues resulted in complete inhibition of the G protein-insensitive MOR internalization. Therefore, agonist-induced MOR down-regulation appears to be mediated by two distinct cellular signal transduction pathways. One is G protein-dependent and GRK-dependent, which can be abolished by pertussis toxin treatment of wild type MOR or by mutagenesis of Thr394. The other novel pathway is G protein-independent but tyrosine kinase-dependent, blocked by genistein treatment, and one in which Thr394 has no regulatory role but phosphorylation of tyrosine residues appears essential.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Although the acute actions of opioids can induce a number of beneficial effects including analgesia and euphoria, chronic use of opioids produces tolerance and dependence (1, 2), which are among the major factors limiting the clinical use of these compounds. The molecular mechanisms underlying these phenomena are poorly understood, but receptor desensitization has been implicated as having a major role.

It has been shown that opioid receptor desensitization is directly related to receptor phosphorylation (3-5), possibly mediating receptor down-regulation (6, 7). A role for several kinases has been postulated in opioid receptor desensitization, including cAMP-dependent protein kinase (PKA)1 (4), calcium-dependent protein kinase (PKC) (4, 8), G protein-coupled receptor kinase (GRK) (5, 9), and mitogen-activated protein kinase (10). A large body of evidence for many G protein-coupled receptors supports the contention that phosphorylated receptors are translocated into the cytosol through binding of arrestin to the phosphorylated receptor. Thus, phosphorylation of the receptors appears to be the prerequisite event for receptor down-regulation (11, 12). In addition to the general involvement of kinases in receptor function, specific phosphorylation sites have been mapped in the third intracellular loop and the carboxyl tail of the muscarinic cholinergic receptor and beta 2 adrenergic receptor (beta 2AR) (12, 13). However, few studies have directly addressed the involvement of receptor phosphorylation in the down-regulation of opioid receptors. In the case of the delta  opioid receptor, deletion of the carboxyl tail of receptor expressed in CHO cells completely abolished receptor down-regulation, suggesting that the carboxyl tail is the necessary structural determinant for delta  opioid receptor down-regulation (15, 16). In contrast to this study, the same delta  opioid receptor deletion mutant expressed in HEK 293 cells showed the identical degree of receptor internalization compared with the wild type delta  opioid receptor in the absence of any detectable phosphorylation, suggesting that phosphorylation of G protein-coupled receptors may not be an absolute requirement for receptor internalization (17).

In the case of the µ opioid receptor (MOR), the reduction of total membrane receptors appears to be the major mechanism for functional desensitization of the MOR (7, 9). Furthermore, we and others have reported that the structural determinants necessary for agonist-induced MOR desensitization are Thr394 and its preceding acidic amino acid stretch (6, 9). Thus, in present study, we examined the further functional roles of these amino acid residues in the carboxyl tail to establish the structural determinants mediating MOR down-regulation.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Generation of Mutants and Stable Cell Lines Expressing Wild Type or Mutant Receptors-- The full-length cDNA for the rat MOR was cloned into the mammalian expression vector pRC/CMV (InVitrogen, San Diego, CA). This construct was used as a template for mutagenesis and for subsequent stable transfection of the wild type and mutant receptor cDNAs into CHO cell lines. Mutant MORs such as T394A, T/S363-383A (AT), T/S363-379AT (ATT) (see Fig. 1), and 4YF (Y87F, Y92F, Y165F, and Y336F) (see Fig. 5B) were constructed by substituting single or multiple amino acid residues. Site-directed mutagenesis was performed using a polymerase chain reaction-based technique as described (18). Briefly, oligonucleotide primers corresponding to unique Eco47III/ApaI restriction sites (located at amino acids 304-305 and at 3'-region of vector, respectively) or NotI (located at the 5'-region of vector)/Eco47III were utilized in combination with two mutagenic primers. Polymerase chain reaction fragments were digested with unique restriction enzymes and subcloned into the corresponding restriction sites of the pRC/CMV encoding a MOR construct. All mutations were verified by dideoxy sequencing. For stable expression, the cell line CHO K-1 (number CCL61; American Type Culture Collection) was grown to 60% confluency in a 100-mm dish and subsequently transfected with wild type or mutant constructs in pRC/CMV vector using a calcium phosphate transfection kit (Life Technologies, Inc.) according to the manufacturer's recommendations. Stable transfectants were selected in 1 mg/ml geneticin (Life Technologies, Inc.), and clones with the appropriate expression level were screened by radioligand binding assay. 30-90 clones expressing varying numbers of receptors were screened to select those with comparable expression levels.

Desensitization Conditions and Adenylyl Cyclase Assay-- CHO cells expressing wild type or mutant MORs at confluent monolayer were treated with either medium alone or 1 µM DAMGO (final concentration) and incubated for 1 h at 37 °C in 5% CO2. Incubation was terminated by washing plates three times with 12 ml of ice-cold PBS. Membranes were prepared as described above. Adenylyl cyclase assays were conducted essentially as described previously (9). The assay mix contained 20 µl of membrane suspension (15-20 µg of protein), 12 µM ATP, 0.1 mM cAMP, 53 µM GTP, 2.7 mM phosphoenopyruvate, 0.2 unit of pyruvate kinase, 1 unit of myokinase, and 0.13 µCi of [32P]ATP in a final volume of 50 µl. Enzyme activities were determined in triplicate assay tubes containing increasing concentrations (10-11-10-3 M) of DAMGO with 10 µM forskolin. Adenylyl cyclase activity was also measured in the presence of buffer alone (basal) or forskolin alone and incubated at 27 °C for 20 min. Reactions were stopped by the addition of 1 ml of an ice-cold solution containing 0.4 mM ATP, 0.3 mM cAMP, and [3H]cAMP (25,000 cpm). [32P]cAMP and [3H]cAMP were isolated by sequential column chromatography using Dowex cation exchange and aluminum oxide columns. The amount of [3H]cAMP was used to quantify individual column recovery. Data were analyzed by nonlinear least squares regression.

Membrane Preparation and Radioligand Binding Assays-- Cells were grown until apparent confluence and then washed twice with 12 ml of ice-cold PBS, harvested, and centrifuged at 100 × g for 10 min. Cells were then lysed in hypotonic buffer (5 mM Tris-HCl, pH 7.8, 2 mM EDTA, containing a protease inhibitor mixture of 10 mg/ml leupeptin, 5 mg/ml soybean trypsin inhibitor, and 5 mg/ml benzamidine) with a polytron homogenizer (Brinkman Instruments, Westbury, NY) for two 30-s bursts at the 5.5 setting. The lysate was then centrifuged at 100 × g for 10 min to pellet unbroken cells and nuclei. The supernatant was collected and centrifuged at 30,000 × g for 30 min, and the resulting pellet was resuspended in buffer containing 50 mM Tris-HCl, pH 7.8, 5 mM MgCl2, 1 mM EGTA with the protease inhibitor mixture and used immediately for radioligand binding studies. Protein content was determined according to the method of Bradford (19). For saturation experiments, cell membranes (20-30 µg of protein/tube) were incubated with increasing concentrations of [3H]naloxone (specific activity, 58.5 Ci/mmol; NEN Life Science Products) in a total volume of 1 ml. Specific binding was determined by calculating the difference in binding of the radiolabeled ligand in the absence and presence of the µ-selective antagonist naltrexone (10 µM). Competition experiments were performed using [3H]naloxone at approximately its Kd value and competing cold drug, DAMGO, at concentrations ranging from 10-11 to 10-4 M. After 2 h of incubation at room temperature, bound ligand was isolated by rapid filtration through a 48-well cell harvester (Brandel, Montreal, Quebec, Canada) onto GF/C Whatman filters. Filters were washed with 10 ml of ice-cold 50 mM Tris-HCl, pH 7.4, and placed in glass vials with 5 ml of scintillation fluid (Cytoscint; ICN, Costa, Mesa, CA) and counted for tritium. All experiments were performed in duplicate, and each experiment was repeated at least three times.

Pretreatment Conditions of Stably Transfected Cells with Various Drugs-- To cause the down-regulation of receptors, CHO cells expressing wild type or mutant MOR at confluent monolayer were treated with either medium alone or 1 µM DAMGO (final concentration) and incubated for 1 h at 37 °C in 5% CO2. To study the down-regulation of receptors, cells were pretreated with different kinase inhibitors for 15 min before adding 1 µM DAMGO, and treatment was continued through the incubation with DAMGO. Pertussis toxin (1 µg/ml) was incubated for 24 h before treating with 1 µM DAMGO. Incubation was terminated by washing plates three times with 12 ml of ice-cold PBS. Membranes were prepared as described above and subjected to the binding assays.

Immunoprecipitation and Immunoblotting-- Three 100-mm dishes of CHO cells were used for each of three groups: untransfected CHO, untreated MOR, and MOR treated with 1 µM DAMGO for 1 h. After treatment, each group of cells was washed three times with ice-cold PBS and lysed with Nonidet P-40 buffer (1% Nonidet P-40, 10 mM NaF, 1 mM sodium pervanadate, 0.1 mM phenylmethylsulfonyl fluoride, 5 mg/ml leupeptin, 10 mg/ml soybean trypsin, and 10 mg/ml benzamide in PBS buffer) for 20 min. Supernatant was collected after centrifugation at 150,000 × g for 15 min, assayed for protein concentration by the Bradford method (19), and precleared by 100 µl of presoaked protein A-agarose beads (Upstate Biotech, Lake Placid, NY). For immunoprecipitation, 1 ml of the precleared supernatant was incubated for 2 h with an antiserum (1:500) directed against 18 amino acids of the proximal carboxyl tail of MOR, and further incubated with 60 µl of the bead slurry for 2 h. Beads were washed five times by resuspension with 0.5% Nonidet P-40 buffer followed by microcentrifugation, and immunoprecipitated proteins were dissociated from beads by extraction with 60 µl of SDS-polyacrylamide gel loading buffer (4% SDS, 25 mM Tris-HCl, pH 6.8, 5% glycerol, 0.5% 2-mercaptoethanol, and 0.005% bromphenol blue). 150 µl of the immunoprecipitated protein were separated on 7% SDS-polyacrylamide gels with prestained protein marker (Helixx Technologies, San Diego, CA). The proteins on the gel were subsequently electrotransferred to a nitrocellulose membrane (Schleicher & Schuell). After blocking with 10% milk, proteins were detected with horseradish peroxidase-conjugated anti-phosphotyrosine (Upstate Biotech) according to the manufacturer's recommendation or detected with MOR antibody (1:5000) by immunoprecipitation. Tyrosine phosphorylated proteins were visualized with an enhanced chemiluminescence system (Amersham Pharmacia Biotech), and precipitated MORs were also visualized using horseradish peroxidase-conjugated anti-rabbit secondary antibody detection (1:3000).

Data Analysis-- The binding data from saturation and competition experiments were fit by nonlinear least squares regression using the data analysis program LIGAND (20). Data from multiple experiments were averaged and expressed as the means ± S.E. The results were considered significantly different when the probability of randomly obtaining a mean difference was <0.05 using the paired Student's t test.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

We have previously reported that the MOR is desensitized after 1 h of treatment with an agonist, 1 µM DAMGO (7). The underlying mechanism of this agonist-induced form of desensitization is likely phosphorylation of MOR, because mutation of a potential GRK phosphorylation site, Thr394 in the carboxyl tail of MOR, completely abolished agonist-induced desensitization (9). During 1 h of DAMGO exposure, the absolute number of MOR in the high affinity state was reduced, resulting from a reduction in total membrane receptors, and this seemed to be the major mechanism causing functional desensitizaton (7). Therefore, we have investigated the possible role of specific carboxyl tail residues including GRK-dependent phosphorylation sites in MOR down-regulation (Fig. 1).


View larger version (6K):
[in this window]
[in a new window]
  		Fig. 1.   Schematic representation showing the positions of the amino acid substitutions at potential phosphorylation sites in the carboxyl tail of MOR. In wild type MOR (WT), bold letters indicate the eight potential phosphorylation sites, serine(s)/threonine(s). The numbers above denote the amino acid positions in the receptor protein. In mutant MORs (T394A, AT, and ATT), bold letters indicate the sites of substitution of serine/threonine by alanine, and the dashed line indicates no changes from wild type.

With wild type MOR, [3H]naloxone competition by DAMGO following exposure to agonist for 1 h showed that the total number of receptors was decreased by 34 ± 1.6% (n = 6) compared with that of untreated membranes (Fig. 2A). The proportion of receptors in the agonist-detected high affinity state and in low affinity state (Table I) remained unchanged following treatment with DAMGO, suggesting that prolonged exposure of agonist did not affect the coupling of wild type MOR to G protein (Fig. 2B). We tested the involvement of Thr394 and the proximal 7 serine/threonine amino acid residues in agonist-induced MOR down-regulation. Interestingly, none of these mutations resulted in complete abolishment of receptor down-regulation, even though only the T394A mutant receptor showed complete inhibition of DAMGO-induced desensitization. However, compared with wild type receptor, T394A mutant receptors were down-regulated to a lesser extent following agonist exposure; 34 ± 1.6% (n = 6) for wild type, 14.8 ± 3.19% (n = 8) for the T394A receptor (Fig. 2A). The AT mutant receptor (Fig. 1) showed desensitization of DAMGO inhibition of forskolin-stimulated cAMP accumulation after 1 h of agonist treatment, with maximal inhibition that was only 70% of that observed with wild type receptor (9). This mutant receptor also showed down-regulation of receptor by 21.7 ± 1.95% (n = 4), which was 64% of wild type MOR down-regulation (p < 0.05) (Fig. 2A). The ATT mutant (Fig. 1) showed an identical degree of desensitization compared with wild type receptor (9). This mutant receptor also showed an identical degree of receptor down-regulation (29.9 ± 0.2%, n = 3, p > 0.05) compared with the wild type receptor (Fig. 2A). Down-regulation of the AT and ATT mutant receptors were significantly different from each other (p < 0.05), suggesting that these receptors differing by a single amino acid demonstrated differential capabilities of agonist-induced down-regulation. However, these mutations did not affect agonist affinity or proportion of receptors in the high affinity and the low affinity states (Table I) compared with wild type receptor, just as shown for the T394A mutant (Fig. 2C), indicating that the properties of G protein coupling were identical to that of wild type MOR. These data imply that the mutated residues in the carboxyl tail of MOR are not involved in G protein coupling but may serve as site(s) regulating down-regulation and desensitization. Furthermore, all mutant receptors displayed the identical degree of agonist-mediated maximal inhibition of adenylyl cyclase activity and also similar IC50 values (Table II), indicating that the mutant receptors retained the ability to stimulate the adenylyl cyclase effector system through normal G protein activation, even though they differed with respect to receptor down-regulation (Fig. 2A). This strongly suggests that MOR down-regulation is independent of G protein activation.


View larger version (15K):
[in this window]
[in a new window]
  		Fig. 2.   Effects of substitution of serines and threonines in the carboxyl tail of the MOR on agonist-induced receptor down-regulation. A, CHO cells expressing wild type or mutant receptors were incubated in the absence and presence of 1 µM DAMGO for 1 h, and subsequently, saturation binding was estimated using increasing concentrations of [3H]naloxone. The percentages of DAMGO-induced receptor down-regulation are presented as the means ± S.E. of at least three independent experiments. Significant difference from wild type is denoted by an asterisk (p < 0.05). B and C, CHO cells expressing either wild type (B) or T394A mutant receptor (C) were incubated in in the absence () and presence (open circle ) of 1 µM DAMGO for 1 h and subjected to competition binding assay. Experiments were conducted in triplicate and repeated 6-8 times. Representative data are shown.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Binding parameters for the stably transfected wild type or mutant µ opioid receptors
KH, and KL, Ki values of the high (H) and low (L) affinity states; RH and RL, proportions of receptor in high (H) and low (L) affinity states. Kd and Bmax values of naloxone binding were determined by saturation binding assay. Ki and proportion of high and low affinity states were determined by competition assay. The binding data from saturation and competition experiments were fitted by nonlinear least squares regression using the data analysis program LIGAND. Data shown are the means ± S.E. of three independent experiments.

                              
View this table:
[in this window]
[in a new window]
 
Table II
Functional properties of wild type and mutant MORs
IC50 is the concentration yielding half-maximal functional response. Values shown are the means ± S.E. from at least three independent experiments.

To determine the involvement of G protein activation in MOR down-regulation, CHO cells expressing wild type MOR were treated with 1 µg/ml of pertussis toxin for 24 h to uncouple the receptor from G proteins. Membranes treated with pertussis toxin were then exposed to DAMGO for 1 h. Pertussis toxin treatment resulted in a complete loss of the agonist detected high affinity state, with receptor existing in a single low affinity, indicating complete uncoupling from G protein (Fig. 3A). However, DAMGO-induced down-regulation of MOR still occurred after pertussis toxin treatment. The down-regulation of MOR by agonist following pertussis toxin treatment was confirmed by Scatchard analysis of [3H]naloxone saturation isotherms (Fig. 3A, inset). The reduction of cell surface receptors by DAMGO in pertussis toxin treated membranes was 21.65 ± 3.75% (n = 3) of that observed with pertussis toxin treatment alone (Fig. 3B). This degree of down-regulation was significantly different from wild type MOR (34 ± 1.6% n = 6) but not different from the T394A mutant receptor down-regulation (14.8 ± 3.2, n = 8) (Fig. 3B). Therefore, agonist-induced MOR down-regulation was reduced by 40% with pertussis toxin treatment, indicating partial dependence on G protein activation. However, the residual MOR down-regulation unaffected by pertussis toxin treatment was therefore clearly independent of G protein activation. Thus, it is tempting to speculate that MOR down-regulation, which is partially blocked by the T394A mutation, may be dependent on G protein activation and GRK-dependent phosphorylation, whereas the residual down-regulation seen in the T394A mutant or after pertussis toxin treatment may be independent from G protein activation and, further, independent from GRK-dependent phosphorylation. This led us to test the possibility that the agonist may induce MOR down-regulation through activation of protein kinases other than GRKs.


View larger version (22K):
[in this window]
[in a new window]
  		Fig. 3.   DAMGO competition of [3H]naloxone binding following treatment of MOR with pertussis toxin. A, CHO cells expressing wild type MOR were incubated with 1 µg/ml of pertussis toxin for 24 h and further incubated in the absence () and presence (open circle ) of 1 µM DAMGO for 1 h. Subsequently, membranes were prepared and incubated with 2 nM [3H]naloxone and increasing concentrations of DAMGO. For saturation binding, membrane was incubated with increasing concentrations of [3H]naloxone. Scatchard analysis of the saturation isotherms is presented in the inset. Experiments were repeated at least three times and representative data are shown. B, the effect of exposure to DAMGO for 1 h to reduce cell surface receptor expression in wild type MOR (WT), wild type treated with pertussis toxin (WT+PTX), and the T394A mutant. Data are expressed as the means ± S.E. The asterisk indicates a significant difference from wild type using the two-tailed Student's t test (p < 0.05).

To determine the identity of the kinases involved in G protein-independent receptor down-regulation, we used a panel of kinase activators and inhibitors. Because there are several reports of the possible role of PKA or PKC on receptor phosphorylation (4, 8) and the target motif is present in the third intracellular loop of MOR, we first examined for involvement of these kinases. To test the possibility of PKA involvement in MOR down-regulation, H89-dihydrochloride was used to inhibit PKA activation. CHO cells expressing wild type MOR were treated with H89-dihydrochloride 5 µM for 15 min prior to and during 1 µM DAMGO treatment for 1 h. The PKA activator, 8-bromo cAMP 100 µM, was also tested without pretreatment with DAMGO to determine whether PKA involvement was an agonist-specific phenomenon. In the same way, the PKC inhibitor, bis-indolylmaleimide I (1 µM) and activator, phorbol 12-myristate 13-acetate (1 µM) were also tested. Surprisingly, neither PKA nor PKC inhibitors blocked agonist-induced MOR down-regulation (Fig. 4A). The PKA inhibitor resulted in increased DAMGO-induced MOR down-regulation (45.5 ± 3.2%, n = 4), whereas the PKA activator alone did not affect MOR down-regulation (Fig. 4A). MOR down-regulation by agonist in the presence of the PKC inhibitor was unaffected (37.63 ± 2.5%, n = 4), and the PKC activator alone did not cause any changes in receptor down-regulation (Fig. 4A). However, the tyrosine kinase inhibitor, genistein (final concentration, 100 µM) partially blocked DAMGO-induced MOR down-regulation (17.3 ± 3.3%, n = 4) by 50% compared with wild type MOR (Fig. 4A). But genistein in the absence of DAMGO without activation of MOR did not affect the receptor density on the cell surface (data not shown), indicating that MOR down-regulation because of activation of tyrosine kinase was agonist-specific. Furthermore, the blockade of MOR down-regulation using genistein was saturable, suggesting that genistein could not block MOR down-regulation further with higher concentrations (data not shown).


View larger version (21K):
[in this window]
[in a new window]
  		Fig. 4.   Effects of different protein kinase activators and inhibitors on MOR down-regulation. A, protein kinase inhibitors (I) were added to the cells expressing wild type MOR 15 min prior to addition of DAMGO and were present throughout DAMGO treatment for 1 h (cross-hatched bars). Wild type MOR was incubated with kinase activators (A) without DAMGO treatment (open bars). PTK, protein-tyrosine kinase. The asterisk indicates that DAMGO-induced MOR down-regulation in the presence of the PTK inhibitor was significantly different from wild type control (p < 0.05). B, DAMGO-induced T394A mutant receptor down-regulation was tested with pertussis toxin or protein-tyrosine kinase inhibitor. The asterisk indicates that DAMGO-induced receptor down-regulation of T394A and T394A treated with pertussis toxin (T394A + PTX) were significantly different from wild type receptor (WT) (p < 0.05). The double asterisks indicate that T394A mutant receptor down-regulation in the presence of tyrosine kinase inhibitor (T394A + PTK) was significantly different from T394A control (p < 0.05). Data are presented as the means ± S.E.

Because the study of wild type MOR suggested that receptor down-regulation was partially G protein-independent and genistein sensitive, we examined whether this was dependent on tyrosine kinase activation. Because DAMGO-induced receptor down-regulation was present in the T394A mutant receptor (14.8 ± 3.2%) (Fig. 3B), we first tested whether this residual T394A mutant receptor down-regulation was also G protein-independent. CHO cells expressing the T394A mutant receptor were treated with 1 µg/ml pertussis toxin for 24 h prior to DAMGO treatment, and receptor down-regulation was compared with cells treated with pertussis toxin alone. Indeed, DAMGO-induced T394A mutant receptor down-regulation occurred even following pertussis toxin treatment, and its extent (13.15 ± 0.8%, n = 3) was identical to that of pertussis toxin untreated membranes (14.8 ± 3.2%) (Fig. 4B), suggesting that DAMGO-induced T394A mutant receptor down-regulation was entirely G protein-independent.

We further tested whether the G protein-independent T394A mutant receptor down-regulation could be blocked by the tyrosine kinase inhibitor. When CHO cells expressing the T394A mutant receptor were treated with 100 µM genistein, down-regulation of receptors because of DAMGO exposure was completely blocked (Fig. 4B). We therefore explored the possibility that MOR might be a direct substrate for tyrosine kinase. When wild type MOR expressed in CHO cells was precipitated using the anti-MOR antibody and probed with an anti-phosphotyrosine antibody, a tyrosine-phosphorylated protein of ~70 kDa appeared only in the transfected cells exposed to DAMGO (Fig. 5A, lane 3 in upper panel). Similar amounts of MOR protein were detected in transfected but agonist-untreated cells when the anti-MOR immunoprecipitates were Western blotted (Fig. 5A, lanes 5 and 6 in lower panel). Because there are four tyrosine residues in intracellular loops and the carboxyl tail that may serve as potential phosphorylation sites (Fig. 5B), we mutated all four tyrosines to phenylalanine (4YF) to test whether these residues were functionally involved in MOR down-regulation. The 4YF mutant receptor stably expressed in CHO cells consistently demonstrated a low expression level in 45 cell lines screened, suggesting that some or all of these tyrosine residues may have a role in cell surface expression (Table II). We have previously reported that the receptor expression level did not affect the degree of DAMGO-induced receptor down-regulation (7). Interestingly, the 4YF mutant receptor showed comparable receptor down-regulation with the T394A receptor: 14.53 ± 3.8% (n = 3) for 4YF (Fig. 5C) and 14.8 ± 3.19% for T394A receptor (Fig. 2A), suggesting that the G protein-dependent pathway was still active in the 4YF mutant receptor.


View larger version (18K):
[in this window]
[in a new window]
  		Fig. 5.   Detection of MOR tyrosine phosphorylation upon receptor activation and direct involvement of tyrosine residues on receptor down-regulation. A, untransfected CHO cells and CHO cells stably expressing MOR were incubated in the absence and presence of 1 µM DAMGO for 1 h and subsequently lysed and immunoprecipitated with anti-MOR antibody. The immunopurified proteins were separated by 7% SDS-polyacrylamide gel electrophoresis, and tyrosine-phosphorylated protein was detected by horseradish peroxidase-conjugated anti-phosphotyrosine antibody. The upper panel and lower panel (immunoprecipitated (i.p.) and immunoblotted (i.b.)) show untranfected (UT) CHO (lanes 1 and 4), MOR transfected untreated with DAMGO (lanes 2 and 5), and MOR transfected, DAMGO-treated (lanes 3 and 6) membranes. B, schematic representation showing the position of tyrosine residues that were substituted to phenylalanines. The numbers above denote the tyrosine position in the receptor protein, and the intracellular loops and carboxyl tail are indicated as IC and CT, respectively. C, agonist-induced down-regulation of tyrosine substituted mutant receptor (4YF). CHO cells expressing the 4YF mutant receptor were incubated in the absence and presence of 1 µM DAMGO for 1 h, and subsequently saturation binding was done using [3H]naloxone. CHO cells expressing the 4YF were also incubated with 1 µg/ml pertussis toxin for 24 h and further incubated for 1 h in the absence and presence of 1 µM DAMGO, and membranes were assayed for saturation binding. The percentages of DAMGO-induced receptor down-regulation are presented as the means ± S.E. of at least three independent experiments. Significant difference from wild type is denoted by an asterisk (p < 0.05), and the double asterisks indicate significant difference from 4YF (p < 0.05).

To examine the involvement of G protein-dependent receptor down-regulation in the 4YF mutant, cells expressing this receptor were treated with pertussis toxin. DAMGO-induced 4YF mutant receptor down-regulation was completely abolished by pertussis toxin treatment (1 ± 1.6%, n = 3) in Fig. 5C, indicating that the residual receptor down-regulation observed in 4YF was entirely due to the G protein-dependent pathway mediated by Thr394 and, further, that the tyrosine residues mutated were functionally involved in receptor down-regulation. Thus, MOR down-regulation seems to be governed by two distinct and mutually exclusive cellular signal transduction pathways.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Our results demonstrate that MOR down-regulation is dually regulated by two distinct equally important cellular signal transduction pathways; one is a G protein dependent, GRK-dependent pathway, and the other is a G protein-independent, tyrosine kinase-dependent pathway. Agonist-induced down-regulation of G protein-coupled receptors has been proposed to be due to phosphorylation of the agonist-bound form of the receptors and subsequent internalization, because of binding of arrestin to the phosphorylated form of receptors (reviewed in Refs. 11 and 12). The recognition sites for the G protein-coupled receptor kinases have been identified as repeated serines and threonines mostly in the carboxyl tail, by phosphopeptide sequencing of high pressure liquid chromatography purified peptides derived from proteolysis of phosphorylated receptors (21, 22). However, the involvement of these amino acid residues in receptor down-regulation has been unclear. For instance, Strader et al. (23) reported that a mutant hamster beta 2AR lacking both the GRK-dependent phosphorylation sites and the putative PKA sites in the carboxyl terminus was sequestered normally in response to the agonist, isoproterenol. In contrast to this study, using a chimeric beta 3/beta 2AR in which single or multiple intracellular domains and carboxyl tail of the beta 2AR were exchanged with the corresponding regions of the beta 3-adrenergic receptor, Jockers et al. (14) have shown the involvement not only of the carboxyl tail of beta 2AR but also the second intracellular loop in receptor sequestration. Because a chimeric receptor, in which the carboxyl tail of beta 2AR containing GRK-dependent phosphorylation sites was exchanged into beta 3-adrenergic receptor, did not show beta 2AR like sequestration, this result suggested that factors other than GRK-dependent ones may be involved in receptor sequestration. However, in certain other receptor systems, there is evidence that receptor down-regulation may be solely due to GRK-dependent phosphorylation. For instance, in the case of the human muscarinic cholinergic receptor types 1 and 3, serine/threonine rich domains in the third intracellular loop are involved in receptor internalization; amino acid residues ESLTSSE for type 1 and ENSASSD for type 3, which are GRK-dependent phosphorylation sites, were the only determinants for receptor internalization (24). Additionally, in the case of the gastrin-releasing peptide receptor, a mutant in which all serines and threonines in the carboxyl tail were deleted showed complete abolishment of receptor internalization (25). However, this deletion mutant receptor showed normal activation of the effector system in increasing total inositol phosphate similar to wild type receptor, indicating that in this case, receptor internalization was regulated independently from receptor-G protein coupling. Furthermore, beta 2AR expressed in the cyc- mutant of S49 cells that are functionally uncoupled from adenylyl cyclase because of an inherent mutant Gs present, still were able to internalize normally (26, 27). These results strongly support distinct and independent mechanisms for G protein activation in signal transduction and for receptor internalization. In our study, the MOR was partly down-regulated by DAMGO even after uncoupling the receptor from G protein by pertussis toxin treatment, indicating that MOR down-regulation was mediated by G protein-independent factors as well. Our results implicate other factors distinct from G protein activation that mediate receptor down-regulation. Because phorphorylation of receptors has been accepted as a prerequisite event leading to receptor internalization (28-31), it is likely that other kinases independent of G protein activation may also be activated directly by ligand binding of receptor to phosphorylate receptors.

What other kinases are likely to be involved? Although PKA-dependent phosphorylation of beta 2AR was known to play an important role in agonist-specific desensitization together with GRK, the direct involvement of this kinase in agonist-induced receptor internalization has not been well characterized (32-35). However, the tyrosine residue (NPXXY), which is highly conserved among G protein-coupled receptors has been reported to be responsible for beta 2AR sequestration (28, 36, 37). Indeed, agonist-induced receptor sequestration was essentially abolished with the Y326A mutant beta 2AR (NPXXA) but was only slightly reduced in the conservatively substituted Y326F receptor (38). This result indicates that this tyrosine residue may not be involved in receptor phosphorylation because of tyrosine kinase activation, but this sequence motif seems to provide the distinct structure for the binding of some other cellular proteins involved in receptor sequestration. However, there has been a substantial body of evidence that tyrosine kinases could be activated through G protein-coupled receptor stimulation. Activation of Gq-coupled m1 muscarinic cholinergic receptor has been shown to activate a Src-related tyrosine kinase, Lyn, and Gi-coupled m2 muscarinic cholinergic receptor has been shown to activate another nonreceptor tyrosine kinase, Syk (39). Furthermore, phosphoamino acid analysis establishes that beta 2AR residues Tyr132, Tyr141, Tyr350/353, and Tyr364 are phosphorylated by insulin in vitro, suggesting that beta 2AR is a substrate for the insulin receptor tyrosine kinase (40). More directly, upon agonist stimulation, the YIPP motif in the carboxyl tail of angiotensin AT1 receptor was reported to be phosphorylated by c-Src tyrosine kinase (41). However, the role of the activation of these tyrosine kinases on G protein-coupled receptor function has been unclear.

In the case of MOR, PKA and PKC have been reported to be differentially related to MOR function (4). Activation of PKC with phorbol ester potentiated the desensitization of MOR-induced G protein-activated K+ channel activity, but injection of the catalytic subunit of PKA completely abolished the desensitization (4). Interestingly, another group reported contradictory results with the same system, where the desensitization of MOR-induced G protein-activated K+ channel activity was not affected by PKA or PKC activation (42). These controversial effects of PKA and PKC on MOR desensitization may be due to effects of these two kinases on other components of the signaling pathways. Furthermore, the PKC inhibitor staurosporine failed to block morphine-induced receptor phosphorylation and subsequent receptor desensitization, although the PKC activator phorbol 12-myristate 13-acetate enhanced receptor phosphorylation (8). Our data showed that PKA or PKC did not affect MOR down-regulation and very likely MOR desensitization following agonist exposure for 1 h. Recently, mitogen-activated protein kinase affecting MOR function has been reported, whereby agonist activation of MOR stimulated mitogen-activated protein kinase activity and, further, promoted receptor desensitization and internalization (10). It has been suggested that activation of MOR increases c-Src tyrosine kinase activity (43), but the consequence of this activation on MOR function has not been elucidated. We have shown for the first time that MOR is directly phosphorylated by a protein-tyrosine kinase upon receptor activation and that this has a significant role in receptor down-regulation. This result confirms our conclusion that GRK-independent protein kinases are also stimulated by MOR activation.

In summary, we have demonstrated that there are two distinct but equally important cellular mechanisms mediating agonist-induced MOR down-regulation; one is a G protein-dependent, GRK-dependent pathway, and the other is a G protein-independent, tyrosine kinase-dependent pathway. One pathway appears unaffected when the other pathway is blocked, and we have identified discrete structural elements that separately participate in each pathway. This is the first demonstration of a role for tyrosine kinase in agonist-induced MOR down-regulation. Further investigation of the specific tyrosine residues that may be substrates for tyrosine kinase action and the other cellular proteins that may participate following tyrosine phosphorylation will elucidate the detailed molecular mechanism of tyrosine kinase activation leading to MOR internalization.

    FOOTNOTES

* This work was supported by grants from the Medical Research Council of Canada, the National Institute on Drug Abuse, and the Smokeless Tobacco Research Council, Inc.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

** To whom correspondence should be addressed: Dept. of Pharmacology, University of Toronto, Medical Sciences Bldg., Rm. 4358, Toronto, ON M5S 1A8, Canada. Tel.: 416-978-3367; Fax: 416-971-2868; E-mail: s.george@utoronto.ca.

    ABBREVIATIONS

The abbreviations used are: PKA, cAMP-dependent protein kinase; PKC, calcium-dependent protein kinase; GRK, G protein-coupled receptor kinase; MOR, µ opioid receptor; CHO, Chinese hamster ovary; DAMGO, [D-Ala2, N-Me-Phe4, Gly-ol5]enkephalin; beta 2AR, beta 2-adrenergic receptor; PBS, phosphate-buffered saline.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Koob, G., Maldonado, R., and Stinus, L. (1992) Trends. Neurosci. 15, 186-191[CrossRef][Medline] [Order article via Infotrieve]
2. Koob, G., and Bloom, F. (1992) Science 242, 715-719
3. Fukushima, N., Ueda, H., Hayashi, C., Katayama, T., Miyamae, T., and Misu, Y. (1994) Neurosci. Lett. 176, 55-58[CrossRef][Medline] [Order article via Infotrieve]
4. Chen, Y., and Yu, L. (1994) J. Bio. Chem. 269, 7839-7842[Abstract/Free Full Text]
5. Pei, G., Kieffer, B. L., Lefkowitz, R. J., and Freedman, N. J. (1995) Mol. Pharmacol. 48, 173-177[Abstract]
6. Koch, T., Schulz, S., Schroder, H., Wolf, R., Raulf, E., and Hollt, V. (1998) J. Biol. Chem. 273, 13652-13657[Abstract/Free Full Text]
7. Pak, Y., Kouvelas, A., Scheideler, M. A., Rasmussen, J., O'Dowd, B. F., and George, S. R. (1996) Mol. Pharmacol. 50, 1214-1222[Abstract]
8. Zhang, L., Yu, Y., Mackin, S., Weight, F. F., Uhl, G. R., and Wang, J. B. (1996) J. Biol. Chem. 271, 11449-11454[Abstract/Free Full Text]
9. Pak, Y., O'Dowd, B. F., and George, S. R. (1997) J. Biol. Chem. 272, 24961-24965[Abstract/Free Full Text]
10. Polakiewicz, R. D., Schieferl, S. M., Dorner, L. F., Kansra, V., and Comb, M. J. (1998) J. Biol. Chem. 273, 12402-12406[Abstract/Free Full Text]
11. Lefkowitz, R. J. (1993) Cell 74, 409-412[CrossRef][Medline] [Order article via Infotrieve]
12. Inglese, J., Freedman, N. J., Koch, W. J., and Lefkowitz, R. J. (1993) J. Biol. Chem. 268, 23735-23738[Free Full Text]
13. Moro, O., Shockley, M. S., Lameh, J., and Sadee, W. (1994) J. Bio. Chem. 269, 6651-6655[Abstract/Free Full Text]
14. Jockers, R., DaSilva, A., Strosberg, A. D., Bouvier, M., and Marullo, S. (1996) J. Biol. Chem. 271, 9355-9362[Abstract/Free Full Text]
15. Trapaidze, N., Keith, D. E., Cvejic, S., Evans, C. J., and Devi, L. A. (1996) J. Biol. Chem. 271, 29279-29285[Abstract/Free Full Text]
16. Cvejic, S., Trapaidze, N., Cyr, C., and Devi, L. A. (1996) J. Biol. Chem. 271, 4073-4076[Abstract/Free Full Text]
17. Murray, S. R., Evans, C. J., and von Zastrow, M. (1998) J. Biol. Chem. 273, 24987-24991[Abstract/Free Full Text]
18. Liggett, S. B., Ostrowski, J., Chesnut, L. C., Kurose, H., Raymond, J. R., Caron, M. G., and Lefkowitz, R. J. (1992) J. Biol. Chem. 267, 4740-4746[Abstract/Free Full Text]
19. Bradford, M. M. (1976) Anal. Biochem. 72, 248-254[CrossRef][Medline] [Order article via Infotrieve]
20. Munson, P. J., and Rodbard, D. (1980) Anal. Biochem. 107, 220-239[CrossRef][Medline] [Order article via Infotrieve]
21. Fredericks, Z. L., Pitcher, J. A., and Lefkowitz, R. J. (1996) J. Biol. Chem. 271, 13796-13803[Abstract/Free Full Text]
22. Palczewski, K., Arendt, A., McDowell, J. H., and Hargrave, P. A. (1989) Biochemistry 28, 8764-8770[CrossRef][Medline] [Order article via Infotrieve]
23. Strader, C. D., Sigal, I. S., Blake, A. D., Cheung, A. H., Register, R. B., Rands, E., Zemcik, B. A., Candelore, M. R., and Dixon, R. A. F. (1987) Cell 49, 855-863[CrossRef][Medline] [Order article via Infotrieve]
24. Moro, O., Lameh, J., and Sadee, W. (1993) J. Biol. Chem. 268, 6862-6865[Abstract/Free Full Text]
25. Benya, R. V., Fathi, Z., Battey, J. F., and Jensen, R. T. (1993) J. Biol. Chem. 268, 20285-20290[Abstract/Free Full Text]
26. Mahan, L. C., Koachman, A. M., and Insel, P. A. (1995) Proc. Natl. Acad. Sci. U. S. A. 82, 129-133
27. Allen, J. M., Abrass, I. B., and Palmiter, R. D. (1989) Mol. Pharmacol. 36, 248-255[Abstract]
28. Ferguson, S. S. G., Downey III, W. E., Colapietro, A.-M., Barak, L. S., Menard, L., and Caron, M. G. (1996) Science 363-366
29. Ranganathan, R., and Stevens, C. F. (1995) Cell 81, 841-848[CrossRef][Medline] [Order article via Infotrieve]
30. Gurevich, V. V., Dion, S. B., Onorato, J. J., Ptasienski, J., Kim, C. M., Sterne-Marr, R., Hosey, M. M., and Benovic, J. L. (1995) J. Biol. Chem. 270, 720-731[Abstract/Free Full Text]
31. Goodman Jr, O. B., Krupnick, J. G., Santini, F., Gurevich, V. V., Penn, R. B., Gagnon, A. W., Keen, J. H., and Benovic, J. L. (1996) Nature 383, 447-450[CrossRef][Medline] [Order article via Infotrieve]
32. Hausdorff, W. P., Bouvier, M., O'Dowd, B. F., Irons, G. P., Caron, M. G., and Lefkowitz, R, J. (1989) J. Biol. Chem. 264, 12657-12665[Abstract/Free Full Text]
33. Lohse, M. J., Benovic, J. L., Caron, M. G., and Lefkowitz, R. J. (1990) J. Biol. Chem. 265, 3202-3209[Abstract/Free Full Text]
34. Inglese, J., Freedman, N. J., Koch, W. J., and Lefkowitz, R. J. (1993) J. Biol. Chem. 268, 23735-23738
35. Winstel, R., Freund, S., Krasel, C., Hoppe, E., and Lohse, M. J. (1995) Proc. Natl. Acad. Sci. U. S. A. 93, 2105-2109[Abstract/Free Full Text]
36. Barak, L. S., Tiberi, M., Freedman, N. J., Kwatra, M. M., Lefkowitz, R. J., and Caron, M. G. (1994) J. Biol. Chem. 269, 2790-2795[Abstract/Free Full Text]
37. Barak, L. S., Menard, L., Ferguson, S. S. G., Colapietro, A.-M., and Caron, M. G. (1995) Biochemistry 34, 15407-15414[CrossRef][Medline] [Order article via Infotrieve]
38. Gabilondo, A. M., Krasel, C., and Lohse, M, J. (1996) Eur. J. Pharmacol. 307, 243-250[CrossRef][Medline] [Order article via Infotrieve]
39. Wan, Y., Kurosaki, T., and Huang, X.-Y. (1996) Nature 380, 541-544[CrossRef][Medline] [Order article via Infotrieve]
40. Baltensperger, K., Karoor, V., Paul, H., Ruoho, A., Czech, M. P., and Malbon, C. C. (1995) J. Biol. Chem. 271, 1061-1064[Abstract/Free Full Text]
41. Ali, M. S., Sayeski, P. P., Dirksen, L. B., Hayzer, D. J., Marrero, M. B., and Bernstein, K. E. (1997) J. Biol. Chem. 272, 23382-23388[Abstract/Free Full Text]
42. Kovoor, A., Henry, D. J., and Chavkin, C. (1994) J. Biol. Chem. 270, 589-595[Abstract/Free Full Text]
43. Mangoura, D. (1997) J. Neurosci. Res. 50, 391-401[CrossRef][Medline] [Order article via Infotrieve]

Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
M. J. Clark and J. R. Traynor
Endogenous Regulator of G Protein Signaling Proteins Reduce {micro}-Opioid Receptor Desensitization and Down-Regulation and Adenylyl Cyclase Tolerance in C6 Cells
J. Pharmacol. Exp. Ther., February 1, 2005; 312(2): 809 - 815.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
I. Tegeder and G. Geisslinger
Opioids As Modulators of Cell Death and Survival--Unraveling Mechanisms and Revealing New Indications
Pharmacol. Rev., September 1, 2004; 56(3): 351 - 369.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
F. Chen and A. J. Lawrence
Chronic Antidepressant Treatment Causes a Selective Reduction of {micro}-Opioid Receptor Binding and Functional Coupling to G Proteins in the Amygdala of Fawn-Hooded Rats
J. Pharmacol. Exp. Ther., September 1, 2004; 310(3): 1020 - 1026.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
W. Wang, H. H. Loh, and P.-Y. Law
The Intracellular Trafficking of Opioid Receptors Directed by Carboxyl Tail and a Di-leucine Motif in Neuro2A Cells
J. Biol. Chem., September 19, 2003; 278(38): 36848 - 36858.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
C. D. Mandyam, D. R. Thakker, and K. M. Standifer
{micro}-Opioid-Induced Desensitization of Opioid Receptor-Like 1 and {micro}-Opioid Receptors: Differential Intracellular Signaling Determines Receptor Sensitivity
J. Pharmacol. Exp. Ther., September 1, 2003; 306(3): 965 - 972.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Lamey, M. Thompson, G. Varghese, H. Chi, M. Sawzdargo, S. R. George, and B. F. O'Dowd
Distinct Residues in the Carboxyl Tail Mediate Agonist-induced Desensitization and Internalization of the Human Dopamine D1 Receptor
J. Biol. Chem., March 8, 2002; 277(11): 9415 - 9421.
[Abstract] [Full Text] [PDF]